References
- Didkowska J, Wojciechowska U. Nowotwory złośliwe w Polsce w 2013 roku. Krajowy Rejestr Nowotworów. Warszawa 2015.
- Markowska A. Epidemiologia i etiopatogeneza raka jajnika W: Markowska J, Mądry R (Red.) Zarys Ginekologii Onkologicznej. Tom II. Termedia, Poznań, 2015.
- Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E on behalf of the ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 2016;27:103-110.
- American College of Obstetricians and Gynecologists. Committee Opinion No. 620. Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015;125:279-281.
- WHO Classification of Ovarian Neoplasms. PathologyOutlines. com: http://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html Dostęp: 01.10.2018.
- Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008;9:1191-1197.
- Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10:296-306.
- Kurman R, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol 2010;33:433-443.
- Nik NN, Vang R, Shih I-M, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol Mech Dis 2014;9:2745.
- Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for casual relationship. Am J Surg Pathol 2007;31:161-169.
- Singh R, Cho KR. Serous tubal intraepithelial carcinoma or not? Metastases to fallopian tube mucosa can masquerade as in situ lesions. Arch Pathol Lab Med 2017;141:1313-1315.
- Trabert B, Coburn SB, Mariani A, Yang HP, Rosenberg PS, Gierach GL, Wentzensen N, Cronin KA, Sherman ME. Reported incidence and survival of fallopian tube carcinomas: a population-based analysis from the North American Association of Central Cancer Registries. J Natl Cancer Inst 2018;110:750-757.
- Venturella R, Lico D, Borelli M, Imbrogno MG, Cevenini G, Zupi E, Zullo F, Morelli M. 3 to 5 years later: Long-term effects of prophylactic bilateral salpingectomy on ovarian function. J Minim Invasive Gynecol 2017;24:145-150.
- McAlpine JN, Hanley GE, Woo MMM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM for the Ovarian Cancer Research Program of British Columbia. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210:471. e1-471.e11.
- Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, D’Alessandro P, Zullo F. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere. Gynecol Oncol 2013;129:448-451.
- Kwon JS. Ovarian cancer risk reduction through opportunistic salpingectomy. J Gynecol Oncol 2015;26:83-86.
- Finlayson S for the BC’s Ovarian Cancer Research Team. Advocating Fallopian Tube removal at the time of hysterectomy to prevent ovarian cancer. http://www.ovcare.ca/prevention/for_health_professionals Dostęp: 01.10.2018.
- Lin YJ, Ou YC, Huang FJ, Lin PY, Kung FT, Lan KC. Ovarian response to gonadotropins in patients with tubal factor infertility: salpingectomy versus nonsalpingectomy. J Minim Invasive Gynecol 2013;20:637-641.
- Skorupska KA, Miotła P. Are there any differences in quality of life and sexual functions after various types of hysterectomy – does prophylactic salpingectomy matter? Ginekol Pol 2016;87:26-31.
- Dilley SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, Straughn Jr JM, Caughey AB, Rodriguez MI. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol 2017;146:373-379.
- Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD et al. for the Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185-192.
- Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
- Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J for the Kommission Ovar of the Gynecologic Oncology Study Group (AGO). Should fallopian tubes be removed during hysterectomy procedures? – A statement by AGO Ovar / Sollen die Tuben im Rahmen der Hysterektomie entfernt werden? – Ein Statement der AGO Ovar. Geburtshilfe Frauenheilkd 2015;75:339-341.
- Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011;70:261-265.
- Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011;121:163-168.
- National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.Dostęp 26.10.2018.
- National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Dostęp: 26.10.2018.
- Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience 2018;12:803.